Clinically meaningful use of blood tumor markers in oncology

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Holdenrieder, Stefan ^a   Pagliaro, Lance ^b   Morgenstern, David ^c   Dayyani, Farshid ^d  

^a UNIVERSITY OF BONN   (Germany)

^b MAYO CLINIC   (United States)

^c Roche Diagnostics Corporation   (United States)

^d Roche Diagnostics Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BETA 2 MICROGLOBULIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CHROMOGRANIN A; CYTOKERATIN 19 FRAGMENT; HUMAN EPIDIDYMIS PROTEIN 4; IMMUNOGLOBULIN; NEURON SPECIFIC ENOLASE; NUCLEIC ACID; PROGASTRIN RELEASING PEPTIDE; PROTEIN S 100; SQUAMOUS CELL CARCINOMA ANTIGEN; THYMIDINE KINASE; THYROGLOBULIN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CLINICAL PRACTICE; DIFFERENTIAL DIAGNOSIS; HUMAN; LIGHT CHAIN; MEANINGFUL USE CRITERIA; ONCOLOGY; PATIENT CARE; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL (TOPIC); BLOOD; MOLECULAR PATHOLOGY; NEOPLASMS; PROCEDURES; PROGNOSIS;

BIOMARKERS, TUMOR; HUMANS; NEOPLASMS; PATHOLOGY, MOLECULAR; PROGNOSIS;

EID: 85006310565     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/9795269     Document Type: Article

References (84)

1. W. Steinberg, "The clinical utility of the CA 19-9 tumorassociated antigen, " The American Journal of Gastroenterology, vol. 85, no. 4, pp. 350-355, 1990
2. M. Hara, Y. Kanemitsu, T. Hirai, K. Komori, and T. Kato, "Negative serum carcinoembryonic antigen has insufficient accuracy for excluding recurrence from patients with Dukes C colorectal cancer: analysis with likelihood ratio, and posttest probability in a follow-up study, " Diseases of the Colon, and Rectum, vol. 51, no. 11, pp. 1675-1680, 2008
3. Centers for Medicare, and Medicaid Services. Clinical Laboratory Fee Schedule (CLAB), 2016, https://www.cms.gov/Medicare/Medicare-fee-for-service-Payment/clinicallabfeesched/index.html
4. M. J. Duffy, J. M. Bonfrer, J. Kulpa, et al., "CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use, " International Journal of Gynecological Cancer, vol. 15, no. 5, pp. 679-691, 2005
5. M. Ducreux, A. S. Cuhna, C. Caramella, et al., "Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up, " Annals of Oncology, vol. 26, supplement 5, pp. v56-v68, 2015
6. J. Bruix, M. Sherman, and American Association for the Study of Liver Diseases, "Management of hepatocellular carcinoma: an update, " Hepatology, vol. 53, no. 3, pp. 1020-1022, 2011
7. C. Verslype, O. Rosmorduc and P. Rougier, "Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment, and follow-up, " Annals of Oncology, vol. 23, supplement 7, pp. vii41-vii48, 2012
8. F. Cardoso, A. Costa, L. Norton, et al., "ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2), " Annals of Oncology, vol. 25, no. 10, pp. 1871-1888, 2014
9. F. Cardoso, A. Costa, L. Norton, et al., "ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2), " Breast, vol. 23, no. 5, pp. 489-502, 2014
10. G. Y. Locker, S. Hamilton, J. Harris, et al., "ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer, " Journal of Clinical Oncology, vol. 24, no. 33, pp. 5313-5327, 2006
11. J. A. Meyerhardt, P. B. Mangu, P. J. Flynn, et al., "Follow-up care, surveillance protocol, and secondary preventionmeasures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement, " Journal of Clinical Oncology, vol. 31, no. 35, pp. 4465-4470, 2013
12. P. R. Carroll, and A. J. Vickers, "Point/counterpoint: Early detection of prostate cancer: do the benefits outweigh the consequences?" Journal of the National Comprehensive Cancer Network, vol. 12, no. 5, pp. 768-771, 2014
13. C. M. Korse, S. Holdenrieder, X.-Y. Zhi, et al., "Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe, and China, " Clinica Chimica Acta, vol. 438, pp. 388-395, 2015
14. K. Huhtinen, P. Suvitie, J. Hiissa, et al., "Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts, " British Journal of Cancer, vol. 100, no. 8, pp. 1315-1319, 2009
15. A. T. Ichiki, S. Krauss, K. L. Israelsen, T. Sonoda, and I. R. Collmann, "Sequential carcinoembryonic antigen levels. A predictor of response, and relapse in combination chemotherapy of advanced gastrointestinal cancer, " Oncology, vol. 38, no. 1, pp. 27-30, 1980
16. A. van der Gaast, C. H. H. Schoenmakers, T. C. Kok, B. G. Blijenberg, F. Cornillie, and T. A. W. Splinter, "Evaluation of a new tumour marker in patients with non-small-cell lung cancer: cyfra 21.1, " British Journal of Cancer, vol. 69, no. 3, pp. 525-528, 1994
17. M. Schwaederle, M. Zhao, J. J. Lee, et al., "Impact of precision medicine in diverse cancers: Ameta-Analysis of phase II clinical trials, " Journal of Clinical Oncology, vol. 33, no. 32, pp. 3817-3825, 2015
18. J. E. Hardingham, P. Grover, M. Winter, P. J. Hewett, T. J. Price, and B. Thierry, "Detection, and clinical significance of circulating tumor cells in colorectal cancer-20 years of progress, " Molecular Medicine, vol. 21, supplement 1, pp. S25-S31, 2015
19. D. F. Hayes, and A. F. Schott, "Personalized medicine: genomics trials in oncology, " Transactions of the American Clinical, and Climatological Association, vol. 126, pp. 133-143, 2015
20. B. T. Li, A. Drilon, M. L. Johnson, et al., "A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced nonsmall-cell lung cancers, " Annals of Oncology, vol. 27, no. 1, pp. 154-159, 2015
21. C. Bettegowda, M. Sausen, R. J. Leary, et al., "Detection of circulating tumor DNA in early-, and late-stage human malignancies, " Science Translational Medicine, vol. 6, no. 224, p. 224ra24, 2014
22. I. Garcia-Murillas, G. Schiavon, B. Weigelt, et al., "Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer, " Science Translational Medicine, vol. 7, no. 302, Article ID 302ra133, 2015
23. K. Kato, J. Uchida, Y. Kukita, et al., "Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response, and disease progression in lung cancer patients, " Scientific Reports, vol. 6, Article ID29093, 2016
24. J. J. Chabon, A. D. Simmons, A. F. Lovejoy, et al., "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients, " Nature Communications, vol. 7, article 11815, 2016
25. J. Tie, Y. Wang, C. Tomasetti, et al., "Circulating tumor DNA analysis detects minimal residual disease, and predicts recurrence in patients with stage II colon cancer, " Science Translational Medicine, vol. 8, no. 346, Article ID 346ra92, 2016
26. P. Sidaway, "Urological cancer: genetics of mCRPC tracked in ctDNA, " Nature Reviews Clinical Oncology, vol. 13, no. 7, p. 398, 2016
27. S. Chang-Hao Tsao, J. Weiss, C. Hudson, et al., "Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF, and NRAS mutations, " Scientific Reports, vol. 5, article 11198, 2015
28. M. J. Joyner, and N. Paneth, "Seven questions for personalized medicine, " The Journal of the AmericanMedical Association, vol. 314, no. 10, pp. 999-1000, 2015
29. J. A. Ledermann, F. A. Raja, C. Fotopoulou, A. Gonzalez-Martin, N. Colombo, and C. Sessa, "Newly diagnosed, and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up, " Annals of Oncology, vol. 24, supplement 6, pp. vi24-vi32, 2013
30. E. Lokich, M. Palisoul, N. Romano, et al., "Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic mass, " Gynecologic Oncology, vol. 139, no. 2, pp. 248-252, 2015
31. D. R. Aberle, A. M. Adams, C. D. Berg, et al., "Reduced lung-cancer mortality with low-dose computed tomographic screening, " New England Journal ofMedicine, vol. 365, no. 5, pp. 395-409, 2011
32. R. S. Wiener, D. R. Ouellette, E. Diamond, et al., "An official American Thoracic Society/American College of Chest Physicians policy statement: the ChoosingWisely top five list in adult pulmonarymedicine, " Chest, vol. 145, no. 6, pp. 1383-1391, 2014
33. R. Molina, R. M. Marrades, J. M. Augé, et al., "Assessment of a combined panel of six serum tumor markers for lung cancer, " American Journal of Respiratory, and Critical CareMedicine, vol. 193, no. 4, pp. 427-437, 2016
34. M. M. Wahidi, J. A. Govert, R. K. Goudar, M. K. Gould, D. C. McCrory, and American College of Chest Physicians, "Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer? ACCP evidence-based clinical practice guidelines (2nd edition), " Chest, vol. 132, supplement 3, pp. 94S-107S, 2007
35. U.-H. Stenman, J. Leinonen, H. Alfthan, S. Rannikko, K. Tuhkanen, and O. Alfthan, "A complex between prostate-specific antigen, and alpha 1-Antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer, " Cancer Research, vol. 51, no. 1, pp. 222-226, 1991
36. W. J. Catalona, A. W. Partin, K. M. Slawin, et al., "Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer frombenign prostatic disease: a prospective multicenter clinical trial, " The Journal of the American Medical Association, vol. 279, no. 19, pp. 1542-1547, 1998
37. H. Grönberg, J. Adolfsson, M. Aly, et al., "Prostate cancer screening in men aged 50-69 years (STHLM3): A Prospective Population-based Diagnostic Study, " The Lancet Oncology, vol. 16, no. 16, pp. 1667-1676, 2015
38. National Comprehensive Cancer Network (NCCN), Occult Primary (Cancer of Unknown Primary [CUP]); Version 1.2015, 2015, http://www.nccn.org/professionals/physiciangls/pdf/occult. pdf
39. T. Muley, Y. He, V. Rolny, et al., "The combination of serum biomarkers CYFRA 21-1, and CEA in the prognostication of early stage non-small cell lung cancer (NSCLC), " Journal of Thoracic Oncology, vol. 10, no. 9, supplement 2, p. S382, 2015
40. T. Muley, X. Zhang, S. Holdenrieder, et al., "Progastrin-releasing peptide (ProGRP) as a biomarker for clinical response in smallcell lung carcinoma (SCLC), " Journal ofThoracic Oncology, vol. 10, no. 9, supplement 2, p. S363, 2015
41. D. Di Gioia, M. Dresse, D. Mayr, D. Nagel, V. Heinemann, and P. Stieber, "Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer, " Clinica Chimica Acta, vol. 440, pp. 16-22, 2015
42. Y. N. Fahmueller, D. Nagel, R.-T. Hoffmann, et al., "CA 15-3 is a predictive, and prognostic biomarker in patients with metastasized breast cancer undergoing selective internal radiation therapy, " International Journal of Clinical Pharmacology, and Therapeutics, vol. 51, no. 1, pp. 63-66, 2013
43. F. G. Ebeling, P. Stieber, M. Untch, et al., "SerumCEA, and CA15-3 as prognostic factors in primary breast cancer, " British Journal of Cancer, vol. 86, no. 8, pp. 1217-1222, 2002
44. F. C. Ebeling, U. M. Schmitt, M. Untch, et al., "Tumour markers CEA, and CA 15-3 as prognostic factors in breast cancer-univariate, and multivariate analysis, " Anticancer Research, vol. 19, no. 4, pp. 2545-2550, 1999
45. D. D. Von Hoff, T. Ervin, F. P. Arena, et al., "Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, " New England Journal ofMedicine, vol. 369, no. 18, pp. 1691-1703, 2013
46. T. Conroy, F. Desseigne, M. Ychou, et al., "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, " The New England Journal of Medicine, vol. 364, no. 19, pp. 1817-1825, 1817
47. A. V. D?Amico, R. Whittington, S. B. Malkowicz, et al., "Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, " The Journal of the American Medical Association, vol. 280, no. 11, pp. 969-974, 1998
48. E. A. Klein, "Tumor markers in testis cancer, " Urologic Clinics of North America, vol. 20, no. 1, pp. 67-73, 1993
49. C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, et al., "National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers, " Clinical Chemistry, vol. 54, no. 12, pp. e11-e79, 2008
50. National Academy of Clinical Biochemistry, Use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers, 2009, https://www.aacc.org/science-And-practice/practice-guidelines/major-Tumor-markers
51. M. K. Accordino, J. D. Wright, S. Vasan, et al., "Serum tumor marker use in patients with advanced solid tumors, " Journal of Oncology Practice, vol. 12, no. 1, pp. 65-66, 2016
52. B. Nakata, Y. S. C. K. Hirakawa, Y. Kato, et al., "Serum CA 125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma, " Cancer, vol. 83, no. 12, pp. 2488-2492, 1998
53. J. S. Frenel, S. Carreira, J. Goodall, et al., "Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration, " Clinical Cancer Research, vol. 21, no. 20, pp. 4586-4596, 2015
54. S.-J. Dawson, D. W. Y. Tsui, M. Murtaza, et al., "Analysis of circulating tumor DNA to monitor metastatic breast cancer, " New England Journal ofMedicine, vol. 368, no. 13, pp. 1199-1209, 2013
55. K. Tjensvoll, M. Lapin, T. Buhl, et al., "Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer, "Molecular Oncology, vol. 10, no. 4, pp. 635-643, 2016
56. V. Stearns, H. Yamauchi, and D. F. Hayes, "Circulating tumor markers in breast cancer: accepted utilities, and novel prospects, " Breast Cancer Research, and Treatment, vol. 52, no. 1-3, pp. 239-259, 1998
57. V. Müller, N. Stahmann, S. Riethdorf, et al., "Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy, and low proliferative activity, " Clinical Cancer Research, vol. 11, no. 10, pp. 3678-3685, 2005
58. L. Lupini, C. Bassi, J. Mlcochova, et al., "Predictionof response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients, " BMC Cancer, vol. 15, no. 1, article no. 808, 2015
59. N. Katakami, S. Atagi, K. Goto, et al., "LUX-lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both, " Journal of Clinical Oncology, vol. 31, no. 27, pp. 3335-3341, 2013
60. F. Petrelli, K. Borgonovo, M. Cabiddu, and S. Barni, "Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated nonsmall-cell lung cancer: a meta-Analysis of 13 randomized trials, " Clinical Lung Cancer, vol. 13, no. 2, pp. 107-114, 2012
61. M. J. O?Shaughnessy, D. R. Feldman, B. S. Carver, and J. Sheinfeld, "Late relapse of testicular germ cell tumors, " Urologic Clinics of North America, vol. 42, no. 3, pp. 359-368, 2015
62. National Comprehensive Cancer Network (NCCN), Testicular cancer; Version 1.2016. 2015, http://www.nccn.org/professionals/physician gls/pdf/testicular.pdf
63. R. Labianca, B. Nordlinger, G. D. Beretta, et al., "Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up, " Annals of Oncology, vol. 24, supplement 6, Article ID mdt354, pp. vi64-vi72, 2013
64. C. Parker, S. Gillessen, A. Heidenreich, and A. Horwich, "Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up, " Annals ofOncology, vol. 26, supplement 5, Article ID mdv222, pp. v69-v77, 2015
65. E. Vizcarra, A. Lluch, R. Cibrian, F. Jarque, and J. Garcia-Conde, "CA 15.3, CEA, and TPA tumor markers in the early diagnosis of breast cancer relapse, " Oncology, vol. 51, no. 6, pp. 491-496, 1994
66. A. C. Pedersen, P. D. Sørensen, E. H. Jacobsen, J. S. Madsen, and I. Brandslund, "Sensitivity of CA 15-3, CEA, and serum HER2 in the early detection of recurrence of breast cancer, " Clinical Chemistry, and Laboratory Medicine, vol. 51, no. 7, pp. 1511-1519, 2013
67. P. Stieber, R. Molina, D. W. Chan, et al., "Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients, " Clinical Laboratory, vol. 49, no. 1-2, pp. 15-24, 2003
68. P. Stieber, and V. Heinemann, "Sinnvoller einsatz von tumormarkern, " The Journal of Laboratory Medicine, vol. 32, pp. 339-360, 2008
69. D. L. Clarke-Pearson, "Screening for ovarian cancer, " The New England Journal of Medicine, vol. 361, no. 2, pp. 170-177, 2009
70. G. J. S. Rustin, M. E. L. van der Burg, C. L. Griffin, et al., "Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial, " The Lancet, vol. 376, no. 9747, pp. 1155-1163, 2010
71. R. C. Bast Jr., "CA 125, and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease, " Cancer, vol. 116, no. 12, pp. 2850-2853, 2010
72. R. T. Morris, and B. J. Monk, "Ovarian cancer: relevant therapy, not timing, is paramount, " The Lancet, vol. 376, no. 9747, pp. 1120-1122, 2010
73. J. N. Primrose, R. Perera, A. Gray, et al., "Effect of 3 to 5 years of scheduled CEA, and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial, " The Journal of the American Medical Association, vol. 311, no. 3, pp. 263-270, 2014
74. J. Niklinski, and M. Furman, "Clinical tumour markers in lung cancer, " European Journal of Cancer Prevention, vol. 4, no. 2, pp. 129-138, 1995
75. R.-F. Wang, B.-R. Song, J.-J. Peng, et al., "The prognostic value of preoperative serum CEA, and CA19-9 values in stage I-III colorectal cancer, " Hepato-Gastroenterology, vol. 61, no. 132, pp. 994-999, 2014
76. I. Heliström, J. Raycraft, M. Hayden-Ledbetter, et al., "The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma, " Cancer Research, vol. 63, no. 13, pp. 3695-3700, 2003
77. U. Menon, A. Ryan, J. Kalsi, et al., "Risk algorithm using serial biomarker measurements doubles the number of screendetected cancers compared with a single-Threshold rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening, " Journal of Clinical Oncology, vol. 33, no. 18, pp. 2062-2071, 2015
78. A. J. Vickers, and S. F. Brewster, "PSA velocity, and doubling time in diagnosis, and prognosis of prostate cancer, " British Journal of Medical, and Surgical Urology, vol. 5, no. 4, pp. 162-168, 2012
79. K. P. Wevers, S. Kruijff, M. J. Speijers, E. Bastiaannet, A. C. Muller Kobold, and H. J. Hoekstra, "S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma, " Annals of Surgical Oncology, vol. 20, no. 8, pp. 2772-2779, 2013
80. S. K. Huang, and D. S. B. Hoon, "Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients, " Molecular Oncology, vol. 10, no. 3, pp. 450-463, 2016
81. C. Charpin, A. K. Bhan, V. R. Zurawski Jr., and R. E. Scully, "Carcinoembryonic antigen (CEA), and carbohydrate determinant 19-9 (CA 19-9) localization in 121 primary, and metastatic ovarian tumors: an immunohistochemical study with the use of monoclonal antibodies, " International Journal of Gynecological Pathology, vol. 1, no. 3, pp. 231-245, 1982
82. R. C. Bast Jr., T. L. Klug, E. St John, et al., "A radioimmunoassay using amonoclonal antibody tomonitor the course of epithelial ovarian cancer, "The New England Journal of Medicine, vol. 309, no. 15, pp. 883-887, 1983
83. L. R. Purves, M. Macnab, and I. Bersohn, "Serum alpha-fetoprotein. I. Immunodiffusion, and immuno-Assay results in cases of primary cancer of the liver, " South African Medical Journal, vol. 42, no. 42, pp. 1138-1141, 1968
84. P. Therasse, S. G. Arbuck, E. A. Eisenhauer, et al., "New guidelines to evaluate the response to treatment in solid tumors, " Journal of the National Cancer Institute, vol. 92, no. 3, pp. 205-216, 2000